Last Updated: November 16, 2026

Investigational Drug Information for Cannabidivarin

« Back to Dashboard


What is the drug development status for Cannabidivarin?

Cannabidivarin is an investigational drug.

There have been 8 clinical trials for Cannabidivarin. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.

The most common disease conditions in clinical trials are Disease, Child Development Disorders, Pervasive, and Autistic Disorder. The leading clinical trial sponsors are GW Research Ltd, Montefiore Medical Center, and GW Pharmaceuticals Ltd.

Recent Clinical Trials for Cannabidivarin
TitleSponsorPhase
Treatment With Cannabis Oil Containing CBD Only or 20:1 CBD:THC vs. Placebo of Persons With ADHDElkana KohnPhase 2
Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case SeriesGregory L Smith, MD, MPHEarly Phase 1
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)Foundation for Prader-Willi ResearchPhase 2

See all Cannabidivarin clinical trials

Clinical Trial Summary for Cannabidivarin

Top disease conditions for Cannabidivarin
Top clinical trial sponsors for Cannabidivarin

See all Cannabidivarin clinical trials

Cannabidivarin Development Update and Market Projection

Last updated: September 4, 2026

Cannabidivarin (CBDV) remains an investigational cannabinoid with no FDA-approved product, no Orange Book listing, and no disclosed commercial launch date. Its principal clinical focus has been epilepsy and autism spectrum disorder (ASD). Public development activity has slowed since Jazz Pharmaceuticals acquired GW Pharmaceuticals in 2021, and CBDV has not emerged as a late-stage pipeline asset.

The base-case commercial projection is zero product revenue through 2028 unless a sponsor restarts clinical development, establishes a clear efficacy signal, and obtains regulatory approval. CBDV’s market opportunity is scientifically credible but commercially unvalidated.

What is cannabidivarin and how does it work?

Cannabidivarin is a non-intoxicating phytocannabinoid structurally related to cannabidiol (CBD). It is also known as CBDV and has the chemical formula C19H26O2. PubChem lists CBDV under CAS Registry Number 2420-56-6 (National Center for Biotechnology Information, 2024).

CBDV has been studied for effects involving:

  • Neuronal excitability and seizure activity
  • TRP channel signaling, including TRPV1
  • GPR55 activity
  • Neuroinflammation
  • Social and behavioral measures relevant to ASD

CBDV does not have the same regulatory or commercial position as cannabidiol. Epidiolex, the approved cannabidiol product, is a separate active ingredient with its own clinical data, labeling, patents, and market authorization.

What clinical indications have been studied for CBDV?

The two principal development areas have been treatment-resistant epilepsy and autism spectrum disorder.

Epilepsy development

GW Pharmaceuticals investigated CBDV as an antiseizure compound before and during the development of Epidiolex. Publicly registered studies evaluated CBDV in epilepsy, including pediatric and young-adult populations.

The epilepsy rationale was based on preclinical anticonvulsant activity and the broader therapeutic interest in phytocannabinoids. CBDV did not produce a publicly disclosed late-stage efficacy package comparable to cannabidiol. No Phase 3 registration or New Drug Application for CBDV has been publicly identified.

Autism spectrum disorder development

CBDV was also evaluated in children and adolescents with ASD. A randomized clinical study examined whether CBDV could improve social responsiveness, repetitive behaviors, irritability, hyperactivity, or other ASD-associated symptoms.

Published clinical work did not establish CBDV as an effective treatment for the core symptoms of ASD. Neuroimaging and mechanistic findings provided signals for additional research but did not substitute for a positive registration-quality efficacy result (Pretzsch et al., 2019; Pretzsch et al., 2021).

Rett syndrome and other neurological uses

Cannabinoid-based therapies have been investigated in several neurodevelopmental disorders, including Rett syndrome. Public evidence supporting CBDV as a late-stage Rett syndrome asset is limited. CBDV should not be grouped with approved or late-stage therapies without a sponsor-confirmed clinical program.

What is the current development status of cannabidivarin?

CBDV is best classified as an early-to-mid-stage investigational compound with no active commercial development program publicly established as of June 2024.

Development attribute Public status
Active ingredient Cannabidivarin, CBDV
Primary sponsors historically associated with development GW Pharmaceuticals; subsequently Jazz Pharmaceuticals
Main indications studied Epilepsy and ASD
FDA approval None
FDA-approved brand None
Orange Book listing None identified
Phase 3 program No publicly established program
Commercial launch None
Biosimilar pathway Not applicable
Generic competition Not applicable because no approved reference product exists
Current commercial visibility Low

GW Pharmaceuticals became a wholly owned subsidiary of Jazz Pharmaceuticals in 2021. The transaction transferred GW’s cannabinoid portfolio and related intellectual property to Jazz, including assets beyond cannabidiol. Jazz’s public pipeline disclosures have not established CBDV as a priority late-stage program (Jazz Pharmaceuticals plc, 2021; 2023).

What FDA regulatory status does CBDV have?

CBDV has no FDA approval and no approved indication. The FDA has not listed a CBDV product as an approved drug in Drugs@FDA, and CBDV has no reference-listed drug status in the Orange Book (U.S. Food and Drug Administration, 2024a; 2024b).

No public evidence establishes:

  • An approved CBDV New Drug Application
  • A CBDV biologics license application
  • A CBDV 505(b)(2) approval
  • An FDA-approved CBDV formulation
  • A listed CBDV method-of-use patent
  • A commercial CBDV labeling date

Any future sponsor would likely require a conventional drug-development pathway involving an Investigational New Drug application, dose-ranging studies, controlled efficacy trials, safety exposure data, chemistry and manufacturing controls, and a marketing application.

Because CBDV is a small molecule, it would generally face an abbreviated new drug application pathway after approval if a qualifying reference product and patent or exclusivity barriers existed. At present, there is no approved CBDV reference product.

What patents protect cannabidivarin?

CBDV patent protection appears more likely to depend on therapeutic-use claims, formulations, combinations, and manufacturing technology than on broad ownership of the molecule itself.

Composition-of-matter protection

CBDV is a naturally occurring phytocannabinoid. Broad composition claims directed solely to naturally occurring CBDV would face prior-art and patent-eligibility challenges, depending on claim construction and jurisdiction. A sponsor’s stronger protection would generally come from:

  • Synthetic production methods
  • Purified or enriched CBDV compositions
  • Defined ratios of CBDV with other cannabinoids
  • Pharmaceutical formulations
  • Specific dosing regimens
  • Treatment of defined patient populations
  • Combination therapy with antiseizure medicines

Method-of-use patents

GW and related entities filed cannabinoid patent families covering therapeutic uses of phytocannabinoids, including seizure disorders and neurological conditions. Public patent records contain families directed to cannabinoid use, formulations, and treatment methods, but the existence of a family does not establish that a currently enforceable claim specifically protects a commercial CBDV product.

The commercial value of method-of-use patents would depend on:

  1. Whether CBDV is expressly claimed rather than included in a broad Markush structure.
  2. Whether the indication and patient population match the proposed label.
  3. Whether the claims survived examination, opposition, post-grant review, or litigation.
  4. Whether patent-term adjustment or patent-term extension is available.
  5. Whether the formulation is necessary to achieve exposure or efficacy.

Formulation protection

CBDV formulation patents could cover oral solutions, capsules, lipid systems, nanoparticle delivery, solid dispersions, or combinations with other cannabinoids. Formulation protection is commercially relevant because cannabinoids can present challenges involving solubility, bioavailability, stability, taste, dose uniformity, and food effects.

No publicly identified CBDV formulation has obtained the market position held by Epidiolex’s oral solution. CBDV therefore lacks an established formulation moat.

Patent-estate assessment

Patent category Likely relevance to CBDV Commercial assessment
Broad CBDV composition Limited by natural-product prior art Potentially weak
Synthetic manufacturing Could protect scalable production Moderate if process-specific
Purified CBDV May protect pharmaceutical-grade material Dependent on claim scope
Epilepsy method of use Potentially valuable if claim expressly covers CBDV Indication and validity dependent
ASD method of use Limited by uncertain clinical efficacy Low to moderate
Oral formulation Could delay formulation competition Not commercially validated
Combination therapy Potentially useful for differentiated labeling Requires clinical support
Manufacturing know-how May create practical barriers Confidential know-how can outlast patents

The overall patent estate should be rated as commercially uncertain rather than strong. The principal weakness is the absence of an approved product and a publicly demonstrated late-stage clinical result.

When does CBDV lose exclusivity?

CBDV has no established FDA exclusivity expiration date because it has not been approved.

The relevant exclusivity categories would be:

  • New chemical entity exclusivity: potentially five years after approval if CBDV qualified as an NCE.
  • Orphan-drug exclusivity: seven years for the approved orphan indication if designated and approved.
  • Pediatric exclusivity: six additional months if applicable.
  • Data exclusivity under a 505(b)(2) or other pathway: dependent on the approval basis.
  • Patent protection: dependent on issued claims, filing dates, terminal disclaimers, and patent-term adjustment.

Orphan designation alone would not create market exclusivity. The compound would need approval for the designated indication.

What patent litigation or Paragraph IV challenges affect CBDV?

No significant public Paragraph IV litigation involving an approved CBDV reference product has been established. That result is expected because CBDV has no FDA-approved reference drug and no Orange Book-listed patents.

Potential litigation would arise only after:

  1. FDA approval of a CBDV product.
  2. Orange Book listing of qualifying patents.
  3. Filing of an abbreviated application referencing the product.
  4. A Paragraph IV certification against one or more listed patents.

Before that point, disputes are more likely to involve patent validity, ownership, inventorship, licensing, or freedom to operate in research and manufacturing.

There is no disclosed CBDV settlement agreement comparable to the patent settlements associated with major approved pharmaceutical products.

Which companies are challenging or competing with CBDV?

No company has publicly established a generic or biosimilar challenge to CBDV. Competitive pressure would come from approved antiseizure medicines and investigational neuropsychiatric compounds.

Competitor Company Commercial position
Epidiolex/Epidyolex, cannabidiol Jazz Pharmaceuticals FDA-approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex
Fintepla, fenfluramine UCB Approved for Dravet syndrome and Lennox-Gastaut syndrome
Diacomit, stiripentol Biocodex Approved for Dravet syndrome in combination regimens
Ztalmy, ganaxolone Marinus Pharmaceuticals Approved for CDKL5 deficiency disorder
Cenobamate SK Biopharmaceuticals and SK Life Science Approved for partial-onset seizures in adults
Soticlestat Takeda Investigational in developmental and epileptic encephalopathies
Other cannabinoid formulations Multiple sponsors Variable regulatory status and evidence

Epidiolex is the most relevant internal comparison because it was developed by GW and is now marketed by Jazz. CBDV would need to demonstrate a meaningful advantage in seizure control, tolerability, dosing, drug interactions, or a distinct indication to justify a separate commercial investment.

How does CBDV compare with cannabidiol?

Attribute CBDV Cannabidiol
FDA approval None Epidiolex approved
Established indication None Specific seizure disorders and tuberous sclerosis complex
Commercial revenue None Established product revenue
Clinical maturity Early-to-mid stage Regulatory-approved
Orange Book status None Listed for Epidiolex
Pediatric evidence Investigational Extensive label-supported evidence
Main development risk Efficacy and program restart Patent expiry and competition
Commercial proof Absent Demonstrated

CBDV cannot currently be valued using Epidiolex revenue multiples without substantial adjustment. Cannabidiol has regulatory validation, physician adoption, reimbursement history, and a defined patient population. CBDV has none of those commercial attributes.

What market could CBDV address?

CBDV’s potential market depends on the indication.

Epilepsy market

The most commercially credible opportunity would be treatment-resistant developmental and epileptic encephalopathies. These disorders have high unmet need, but the market is specialized and requires strong seizure-reduction data. Epidiolex, fenfluramine, ganaxolone, and other agents already compete in this segment.

A successful CBDV product could target:

  • Patients inadequately controlled by existing antiseizure medicines
  • Patients unable to tolerate sedating therapies
  • Pediatric patients with defined genetic or developmental syndromes
  • Combination treatment where CBDV has a favorable interaction profile

Autism spectrum disorder market

ASD would be a substantially larger theoretical market, but regulatory and clinical risk is higher. Core ASD symptoms are difficult to measure, placebo effects are significant, and no cannabinoid has established FDA approval for the disorder. A CBDV product would need reproducible benefit on validated endpoints, not only biomarker or exploratory behavioral findings.

Revenue projection

Scenario Development assumption Revenue outlook
Base case No meaningful restart or no positive pivotal data $0 through 2028
Upside case Program restarted, epilepsy indication selected, positive Phase 2/3 data Commercial entry unlikely before 2029-2031
High case Approval in a defined orphan epilepsy population Potential specialty product; revenue dependent on label and price
ASD expansion case Positive controlled efficacy and broad label Larger theoretical market, but low probability based on current public evidence

A specialty epilepsy launch could support meaningful revenue if CBDV demonstrated differentiated efficacy. The commercial ceiling would likely remain below Epidiolex unless CBDV secured a broader indication or materially better clinical profile.

What manufacturing and geographic IP barriers exist?

CBDV production requires control over cannabinoid identity, purity, isomer profile, residual solvents, impurities, stability, and batch consistency. A pharmaceutical sponsor would need validated manufacturing controls suitable for regulated drug production.

Potential barriers include:

  • Access to pharmaceutical-grade starting materials
  • Control of synthetic or botanical production routes
  • Enantiomeric and isomeric purity
  • Consistent CBDV concentration
  • Scalable oral formulation
  • Analytical reference standards
  • GMP manufacturing capacity
  • Country-specific cannabinoid controls

Geographic patent protection would need to be assessed separately in the United States, Europe, the United Kingdom, Canada, Australia, and major Asian markets. A United States patent would not establish freedom to operate in Europe or other jurisdictions. CBDV’s natural-product origin makes jurisdiction-specific claim scope particularly important.

What are the principal investment and partnering implications?

CBDV is an option-value asset rather than a validated commercial product. The strongest partnering case would require a sponsor to obtain:

  • A clear development-rights position after the GW-to-Jazz asset transfer
  • A current freedom-to-operate analysis
  • New clinical data in a defined seizure population
  • A differentiated pharmacokinetic or safety profile
  • Patent claims that extend beyond the natural molecule
  • A practical route to GMP-scale manufacturing

The absence of an approved product reduces near-term litigation risk but also eliminates established revenue support. A partner would be funding clinical redevelopment, regulatory work, and market creation rather than acquiring a late-stage asset.

Key Takeaways

  • CBDV is an unapproved investigational cannabinoid with historical development in epilepsy and ASD.
  • No FDA approval, Orange Book listing, commercial product, or established exclusivity expiration date exists.
  • The public development program has not progressed to a clearly established Phase 3 or registration stage.
  • GW Pharmaceuticals and Jazz Pharmaceuticals are the central corporate entities associated with CBDV development and rights history.
  • CBDV’s strongest potential patent positions are likely therapeutic-use, formulation, manufacturing, and combination claims.
  • Broad composition protection is less reliable because CBDV is a naturally occurring cannabinoid.
  • No meaningful Paragraph IV challenge, generic launch, biosimilar risk, or CBDV patent settlement has been publicly established.
  • Epidiolex is the key commercial comparator, but CBDV lacks cannabidiol’s regulatory validation and revenue history.
  • The base-case market projection is zero revenue through 2028 without a program restart and positive pivotal data.

FAQs

Is cannabidivarin the same drug as Epidiolex?

No. Epidiolex contains cannabidiol, while CBDV is cannabidivarin. They are chemically related but distinct active ingredients with separate clinical and regulatory profiles.

Can CBDV be sold as a dietary supplement in the United States?

A commercial CBDV product would face FDA and controlled-substance, drug-exclusion, labeling, and safety requirements. Marketing a product for disease treatment would generally raise drug-regulatory issues. CBDV has no FDA-approved therapeutic supplement status.

Does CBDV have orphan-drug potential?

Yes, particularly for narrowly defined developmental and epileptic encephalopathies. Orphan status would require FDA designation and subsequent approval for the qualifying indication. Designation alone would not provide market exclusivity.

Could CBDV be approved through the 505(b)(2) pathway?

Potentially, depending on the sponsor’s reliance on existing safety or pharmacology data and the proposed formulation. A 505(b)(2) pathway would not eliminate the need to establish CBDV-specific safety, dosing, manufacturing, and efficacy requirements.

Is CBDV likely to compete with medical cannabis products?

A prescription CBDV medicine would compete on standardized dose, clinical evidence, physician prescribing, reimbursement, and manufacturing quality. Nonprescription cannabis products would not be direct substitutes for an FDA-approved CBDV product in regulated clinical use.

References

  1. Jazz Pharmaceuticals plc. (2021). Annual report on Form 10-K for the year ended December 31, 2021. U.S. Securities and Exchange Commission.

  2. Jazz Pharmaceuticals plc. (2023). Annual report on Form 10-K for the year ended December 31, 2023. U.S. Securities and Exchange Commission.

  3. National Center for Biotechnology Information. (2024). PubChem compound summary for cannabidivarin. PubChem.

  4. Pretzsch, C. M., Freyberg, J., Voineskos, A. N., et al. (2019). Effects of cannabidiol on brain function and structure in patients with autism spectrum disorder: A pilot study. Molecular Psychiatry.

  5. Pretzsch, C. M., Voineskos, A. N., & others. (2021). Cannabidivarin and neurodevelopmental disorders: Clinical and neuroimaging findings. Translational Psychiatry.

  6. U.S. Food and Drug Administration. (2024a). Drugs@FDA: FDA-approved drugs database.

  7. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.